IHImran Hasan

Imran Hasan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Imran Hasan has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alzheimer’s disease and related dementias in South and Southeast Asia: a systematic review and meta-analysis of epidemiology and associated factors

    by Mantaka Rahman, Tamal Saha, Md Abu Jaher Nayeem, Ashiqa Tabassum, Imtiaz Abdullah, Sharmin Sultana, Israt Jahan, Imran Hasan, Shoma Hayat, Nowshin Papri, et al.

    Objectives: Alzheimer’s disease and related dementias (AD/ADRDs) are rising global public health challenges, disproportionately affecting ageing populations. Although higher prevalence estimates have been reported in high-income countries (HICs), the most rapid increase in dementia burden is projected to occur in low- and middle-income countries (LMICs), particularly in South and Southeast Asia. Genetic predisposition and non-modifiable risk factors interplay with vascular, lifestyle and environmental factors, shaping future disease burden. However, evidence from South and Southeast Asia remains fragmented, limiting targeted policy responses. This review systematically synthesises available evidence on prevalence and associated factors to inform prevention and care strategies. Design: Systematic review and meta-analysis of AD/ADRDs prevalence and associated factors related studies from South and Southeast Asia. Data sources: Five electronic databases including PubMed, Scopus, CINAHL, EMBASE, APA PsycNet and hand searching of reference lists up to 1 May 2025. Eligibility criteria for selecting studies: The designed study included observational studies, specifically cross-sectional, casecontrol and cohort designs that reported the epidemiological characteristics and associated factors of AD/ADRDs. Data extraction and synthesis: Study screening, data extraction and methodological assessments were conducted by two independent reviewers. Risk of bias was assessed using the modified Newcastle-Ottawa Scale (mNOS). A restricted maximum likelihood model was used to synthesise results, complemented by synthesis of associated risk factors. Between-study heterogeneity was assessed using I² statistic. Results: A total of 31 studies were included, of which 13 were analysed to estimate pooled prevalence (N=56 340). The methodological quality was good (mean mNOS=7.1, SD 0.99). The pooled age of onset of AD was 70.7 (SD 5.5) years, with one-third (46.3%) of the men surviving for 5 years. The overall estimated prevalence of dementia was 3.0% (95% CI 2.0% to 5.0%, I 2 =98.7%), AD 2.0% (95% CI 1.0% to 4.0%, I 2 =99.0%) and vascular dementia 1.0% (95% CI 0% to 1.0%, I 2 =93.7%). Subgroup analysis showed that AD prevalence was 3.0% in LMICs (95% CI 1.0% to 6.0%) compared with 2.0% in HICs (95% CI 1.0% to 4.0%), and increased to 8.0% after 2010 (95% CI 5.0% to 14.0%) compared with 1.0% before 2000 (95% CI 0% to 2.0%). Additionally, results suggested that older adults had higher odds of AD (OR: 3.98, 95% CI 1.77% to 8.99%), while higher literacy, adequate sleep, periodontal therapy and cognitive stimulation were identified as protective factors. No clear evidence of an association between female gender, family history and AD risk was observed in the pooled analysis. Conclusions: AD affects a substantial and growing proportion of populations in South and Southeast Asia, with marked heterogeneity across settings. Evidence of an upward trend over the time in LMICs poses significant challenges in the coming years. The rising prevalence, associated factors particularly in resource-limited contexts, underscores the need for early-screening in clinical practices and region-specific epidemiological research. PROSPERO registration number: CRD 420251047105.

  • Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain‐Barré Syndrome

    by Shoma Hayat, Md. Abu Jaher Nayeem, Asaduzzaman Asad, Md. Golam Mostafa, Ruma Begum, Moriam Akter Munni, Ayesha Akter Anjuman, Saima Akhter Sadia, Ismat Jahan Upama, Imran Hasan, et al.

    Background and Aims: The gut‐microbiota plays a significant role in neuro‐autoimmune diseases, like Guillain‐Barré syndrome (GBS), a post‐infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut‐microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. Methods: We enrolled 60 patients with GBS categorized into three treatment groups: IVIg‐treated, PE, and supportive‐care along with 60 age‐sex‐matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2‐Dada2 pipeline. Results: Gut‐microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg‐treated patients, showing significant changes after 6‐month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg‐treated patients toward a healthy state after treatment ( p ≤ 0.001). Phylum Actinobacteriota ( p = 0.026), genera Bifidobacterium ( p = 0.006), and Enterococcus ( p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut‐microbial diversity (Unweighted‐UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia‐Shigella , and Actinomyces in GBS patients. Interpretation: Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg‐treatment outcomes. IVIg‐treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta‐transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.

  • Open Access

    Challenges in Diagnosis and Management of Crohn's Disease in Bangladesh With Long Term Follow‐Up

    by Imtiaz Abdullah, Imran Hasan, Mantaka Rahman, Shoma Hayat, Nowshin Papri, Nusrat Fatema, Ahmedul Kabir, Zhahirul Islam

    Crohn's disease (CD) is a chronic autoimmune inflammatory bowel disease (IBD) with significant diagnostic and therapeutic challenges. We reported a case of a 20‐year‐old Bangladeshi male with an 8‐month history of severe upper abdominal pain, bowel discomfort, and intermittent low‐grade fever. Initial investigations showed mild anemia and elevated inflammatory markers. Magnetic resonance enterography revealed distal small bowel thickening, suggestive of IBD. Colonoscopy and biopsy confirmed chronic ileitis without granulomas and an ulcer at the terminal ileum. Despite the absence of granulomas, clinical symptoms, elevated fecal calprotectin, and high C‐reactive protein (CRP) led to a diagnosis of CD. The disease later progressed to a perianal abscess, a fistulizing complication. The patient received three doses of infliximab but subsequently discontinued therapy. He remained untreated for 3‐years and subsequently developed an intestinal perforation requiring right hemicolectomy with ileostomy. Following ileostomy reversal, adalimumab was advised. This case highlighted the diagnostic and therapeutic challenges of CD in Bangladesh.

  • Open Access

    Molecular epidemiology of Campylobacter jejuni associated with Guillain–Barré syndrome

    by Shoma Hayat, Md. Golam Mostafa, Md. Abu Jaher Nayeem, Ruma Begum, Ayesha Akter Anjuman, Saima Akhter Sadia, Imran Hasan, Asaduzzaman Asad, Zhahirul Islam

    Campylobacter jejuni is the leading cause of bacterial gastroenteritis and its post-infectious sequelae, Guillain-Barré syndrome (GBS). Disease epidemiology of campylobacteriosis differs between high- and low-income countries. The molecular epidemiology of GBS-associated C. jejuni strains has not been thoroughly studied to understand its population dynamics and unique genomic features. We investigated a genome-based epidemiological analysis of 90 GBS-associated C. jejuni strains from 10 different countries to elucidate bacterial genomic features and epidemiological patterns related to GBS induction. We found 11 clonal complexes (CC) and 25 sequence types (STs) with two prevalent lineages, CC-362 (ST-2993) and CC-22(ST-22). SNP-based phylogenetic analysis revealed, the first sequenced C. jejuni (CC-22) from USA was genetically associated with strains from Bangladesh, Mexico, and China. Lipo-oligosaccharide (LOS) class A was prevalent worldwide (63%). In Bangladesh, 32% (9/28) of sialyltransferase cstII-genes harbored a Threonine at 51st-position, compared to China (60%, 6/10), USA (100%, 2/2), and Netherlands (67%, 4/6). Type-VI secretion system was enriched in Bangladesh (11/38, 29%). Among C. jejuni-integrated elements, CJIE-1 was most common (27/90, 30%). Phase variation was significantly higher in CC-403 strains. These diversified genomic characteristics of GBS-associated C. jejuni enhance our understanding of its pathogenic virulence features and linked epidemiological-pattern in Bangladesh and worldwide.


  • Open Access

    Epidemiology and risk factors of Alzheimer’s disease and related dementias in South and Southeast Asia: a systematic review and meta-analysis protocol

    by Mantaka Rahman, Ashiqa Tabassum, Sharmin Sultana, Tamal Saha, Abu Jaher Nayeem, Israt Jahan, Imran Hasan, Shoma Hayat, Nowshin Papri, Zhahirul Islam

    Background: Alzheimer’s disease (AD) impacts over 55 million individuals worldwide and remains the leading cause of dementia (60–70% of cases). By 2050, South and Southeast Asia are projected to have an older adult population more than double, bearing a major share of Alzheimer’s disease burden. This will exert a heavy strain on healthcare systems, particularly in resource-limited countries where support and infrastructure are already stretched. Despite this, no review has yet explored the regional epidemiology and associated risk factors in this context. Thus, this study protocol outlines to synthesise prevailing evidence from these densely populated regions, particularly low- and middle-income nations within South and Southeast Asia. Methods: This review will include studies that reported epidemiological characteristics including prevalence, age of onset, mortality, and risk factors of AD and related dementias comprising in South and Southeast Asian regions. Studies published in any language from inception to date will be extracted from PubMed, Scopus, CINAHL, EMBASE and APA PsycNet, following Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We will also search grey literature sources and screen the reference lists of the articles selected for full-text review to identify additional relevant studies. Observational studies including case–control, cohort, and cross-sectional designs reporting desired outcomes will be included and appraised for quality assessment with the modified Newcastle-Ottawa Scale (mNOS). The included articles will be appraised by two independent reviewers, with a third resolving any conflicts. Pooled estimates of prevalence, age of onset and mortality will be analysed using random effect meta-analysis (REML) model. Associated risk factors, including modifiable and non-modifiable will be narratively synthesised. Forest plots will be used to visualise the findings, and heterogeneity across the included studies will be assessed using the I ² and Cochrane’s Q statistics. Potential publication bias will be assessed using a funnel plot along with the Begg’s and Egger’s tests. Sensitivity and subgroup analyses will also be conducted to assess the robustness of pooled estimates and to explore potential sources of heterogeneity. Statistical analysis will be conducted using Rstudio (v.4.3.2) and GraphPad Prism V.9.0.2. Ethics and disseminations: The systematic review is focused on the analysis of secondary data from published literature; thus, no ethical approval will be needed. The protocol will follow international standard guidelines, findings will be reported in a reputed journal and disseminated through (inter)national conferences, webinars and key stakeholders to inform policy, research and AD management strategies. PROSPERO registration number: CRD 420251047105.


  • Open Access

    Pain determinants and quality of life in Guillain-Barre syndrome: a prospective cohort study

    by Nowshin Papri, Asif Mohammed, Mantaka Rahman, Imran Hasan, Rufydha Azam, Tamal Saha, Farzana Tamanna Ummey Shaon, Israt Jahan, Shoma Hayat, Gulshan Ara, et al.

    Background: Pain is a serious manifestation in both the acute and chronic stages of Guillain-Barre syndrome (GBS). We evaluated the frequency, characteristics and associated factors of pain and its impact on quality of life (QoL) among patients with GBS. Methods: We enrolled 644 patients with GBS from prospective cohort studies in Bangladesh conducted between 2010 and 2024. Data were collected at enrolment and at standard follow-up time points up to 26 weeks. Pain intensity was measured by a pain numeric rating scale. Group differences were tested using the χ² or Fisher’s exact test, longitudinal changes were analysed with repeated-measures analysis of variance and correlations were analysed with Spearman’s rank test. Results: The median age of the patients was 31 years, with 70% men. During enrolment, 71% of patients reported pain, which persisted among 38% at week 13 and 26% at week 26. Pain was significantly associated with disease severity, muscle weakness and treatment with intravenous immunoglobulin in both the acute and chronic stages. Patients with acute pain had a higher proportion of axonal GBS (p=0.000) than those without pain. Chronic pain was associated with higher age (p=0.006), male sex (p=0.000), preceding diarrhoea (p=0.033) and dysautonomia (p=0.000). Higher pain intensity was reported among women (p=0.027), patients with higher age (p=0.029) and severe form of GBS (p=0.038) compared with counter groups. Acute pain was significantly associated with the ‘self-care’ (p=0.023), ‘usual activities’ (p=0.049) and ‘anxiety/depression’ (p=0.048) domains of QoL, whereas chronic pain was associated with the ‘anxiety/depression’ (p=0.005) domain. Conclusions: Pain presented as a serious symptom negatively affecting the QoL in GBS. Systematic evaluation of pain is recommended to ensure a personalised treatment approach for GBS.


  • Clinical and serological prognostic factors in childhood Guillain‐Barré syndrome: A prospective cohort study in Bangladesh

    by Imran Hasan, Nowshin Papri, Shoma Hayat, Israt Jahan, Gulshan Ara, Badrul Islam, Zhahirul Islam

    Guillain‐Barré syndrome (GBS) is the most common cause of acute flaccid paralysis in children. The objective of this study was to investigate the preceding infections, clinical, serological and electrophysiological characteristics and outcome of childhood GBS in Bangladesh. We included 174 patients with GBS aged Campylobacter jejuni serology and anti‐GM1 IgG antibody were positive in 66% and 21% of the patients respectively. One hundred and forty‐three (82%) patients did not receive standard treatment and half of them recovered fully or with minor deficits at 6‐month. Twenty patients (11%) died throughout the study period. At 3‐month of onset of weakness, complete recovery or recovery with minor deficit was significantly higher in demyelinating GBS patients compared to axonal GBS patients (86% vs 51%, P = .001). Cranial nerve palsy (OR = 4.00, 95%CI = 1.55‐10.30, P = .004) and severe muscle weakness (OR = 0.16, 95%CI = 0.06‐0.45, P = .001) were the important risk factors of poor outcome in children with GBS. Further large‐scale studies are required for better understanding of factors associated with mortality and morbidity in childhood GBS.


  • Open Access

    Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis

    by Imran Hasan, Km Saif‐Ur‐Rahman, Shoma Hayat, Nowshin Papri, Israt Jahan, Rufydha Azam, Gulshan Ara, Zhahirul Islam

    Several published reports have described a possible association between Guillain‐Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection. This systematic review aimed to summarize and meta‐analyze the salient features and prognosis of SARS‐CoV‐2‐associated GBS. We searched the PubMed (Medline), Web of Science and Cochrane databases for articles published between 01 January 2020 and 05 August 2020 using SARS‐CoV‐2 and GBS‐related keywords. Data on sociodemographic characteristics, antecedent symptoms, clinical, serological and electrophysiological features, and hospital outcomes were recorded. We included 45 articles from 16 countries reporting 61 patients with SARS‐CoV‐2‐associated GBS. Most (97.7%) articles were from high‐ and upper‐middle‐income countries. Forty‐two (68.9%) of the patients were male; median (interquartile range) age was 57 (49‐70) years. Reverse transcriptase polymerase chain reaction for SARS‐CoV‐2 was positive in 90.2% of patients. One report of SARS‐CoV‐2‐associated familial GBS was found which affected a father and daughter of a family. Albuminocytological dissociation in cerebrospinal fluid was found in 80.8% of patients. The majority of patients (75.5%) had a demyelinating subtype of GBS. Intravenous immunoglobulin and plasmapheresis were given to 92.7% and 7.3% of patients, respectively. Around two‐thirds (65.3%) of patients had a good outcome (GBS‐disability score ≤ 2) on discharge from hospital. Two patients died in hospital. SARS‐CoV‐2‐associated GBS mostly resembles the classical presentations of GBS that respond to standard treatments. Extensive surveillance is required in low‐ and lower‐middle‐income countries to identify and report similar cases/series. Further large‐scale case‐control studies are warranted to strengthen the current evidence. PROSPERO Registration Number CRD42020201673.


  • Open Access

    A Record Review on the Health Status of Rohingya Refugees in Bangladesh

    by Taufique Joarder, Ipsita Sutradhar, Imran Hasan, Mafizul I Bulbul

    The Rohingya refugee crisis is neither new nor a sudden problem for Bangladesh. However, the recent violence in August 2017 instigated the migration of 6,93,000 additional Rohingyas into Bangladesh and as of June 2018, around one million Rohingya refugees were residing in Bangladesh. Against this backdrop, it is important to know their current health status because, without this information, equal and equitable health service provision is not possible. So, we conducted this review to understand the current health status of the Rohingya refugees in Bangladesh. For this purpose, a systematic literature search was conducted in July 2018 using transparent selection criteria and the keywords "Rohingya", "Health", Bangladesh". After screening the title and abstract and removing duplication, 12 articles and 21 organizational reports were found eligible for final review. Major health problems prevailing among Rohingya refugees are unexplained fever, acute respiratory infection, and diarrhea. Non-communicable diseases like hypertension, diabetes, and their risk factors are also highly prevalent among these people. More than half of the Rohingya refugees are women and many of them experience sexual abuse or exploitation. More than 50,000 Rohingya refugee women were pregnant, however, a significant portion of pregnant women did not have access to quality antenatal care. Mental health problems like post-traumatic stress disorder (PTSD), depression, and suicidal thoughts were also commonly prevailing in the Rohingya community.


  • Huntington's disease in Bangladesh

    by Zhahirul Islam, Imran Hasan, Quazi Deen Mohammad